+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Myelogenous Leukemia Treatment: Global Strategic Business Report

  • PDF Icon

    Report

  • 194 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309907

Global Chronic Myelogenous Leukemia Treatment Market to Reach $9 Billion by 2030

The global market for Chronic Myelogenous Leukemia Treatment estimated at US$6 Billion in the year 2022, is projected to reach a revised size of US$9 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2022-2030. Disease Specific Treatment, one of the segments analyzed in the report, is projected to record 6% CAGR and reach US$3.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Symptomatic Treatment segment is readjusted to a revised 5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 4.9% CAGR

The Chronic Myelogenous Leukemia Treatment market in the U.S. is estimated at US$1.8 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Select Competitors (Total 42 Featured) -

  • Bio-Path Holdings, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Incyte Corporation
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Chronic Myelogenous Leukemia Treatment

What is the estimated value of the Global Market for Chronic Myelogenous Leukemia Treatment?

The Global Market for Chronic Myelogenous Leukemia Treatment was estimated to be valued at $6 Billion in 2022.

What is the growth rate of the Global Market for Chronic Myelogenous Leukemia Treatment?

The growth rate of the Global Market for Chronic Myelogenous Leukemia Treatment is 5.2%, with an estimated value of $9 Billion by 2030.

What is the forecasted size of the Global Market for Chronic Myelogenous Leukemia Treatment?

The Global Market for Chronic Myelogenous Leukemia Treatment is estimated to be worth $9 Billion by 2030.

Who are the key companies in the Global Market for Chronic Myelogenous Leukemia Treatment?

Key companies in the Global Market for Chronic Myelogenous Leukemia Treatment include Bio, Path Holdings, Inc., Bristol, Myers Squibb Company, F. Hoffmann, La Roche AG, Incyte Corporation, Novartis AG, Pfizer, Inc. and Teva Pharmaceutical Industries Ltd..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Chronic Myelogenous Leukemia Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Disease Specific Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Symptomatic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Branded by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 16: World Chronic Myelogenous Leukemia Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 18: USA Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: USA 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 20: USA Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: USA 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: Canada 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 26: Canada Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: Canada 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • JAPAN
  • Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: Japan 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 32: Japan Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: Japan 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • CHINA
  • Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 35: China Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: China Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: China 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 38: China Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: China Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: China 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • EUROPE
  • Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 41: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 42: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 44: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • FRANCE
  • Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 50: France Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: France Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: France 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 53: France Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: France Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: France 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • GERMANY
  • Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 56: Germany Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Germany 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 59: Germany Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: Germany 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • ITALY
  • Table 62: Italy Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: Italy 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 65: Italy Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: Italy 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 68: UK Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: UK Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: UK 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 71: UK Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: UK Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: UK 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 74: Rest of Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: Rest of Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 77: Rest of Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: Rest of Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 80: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: Asia-Pacific 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: Asia-Pacific 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 86: Rest of World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: Rest of World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
  • Table 89: Rest of World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Rest of World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bio-Path Holdings, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Incyte Corporation
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.